A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

PHASE3CompletedINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

June 27, 2019

Study Completion Date

June 27, 2019

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

ALKS 8700

Administered as specified in the treatment arm.

DRUG

Dimethyl Fumarate

Administered as specified in the treatment arm.

Trial Locations (67)

11772

Alkermes Investigational Site, Patchogue

11794

Alkermes Investigational Site, Stony Brook

13210

Alkermes Investigational Site, Syracuse

20007

Alkermes Investigational Site, Washington D.C.

23226

Alkermes Investigational Site, Richmond

23601

Alkermes Investigational Site, Newport News

27103

Alkermes Investigational Site, Winston-Salem

27405

Alkermes Investigational Site, Greensboro

28203

Alkermes Investigational Site, Charlotte

29307

Alkermes Investigational Site, Spartanburg

29406

Alkermes Investigational Site, Charleston

29650

Alkermes Investigational Site, Greer

29707

Alkermes Investigational Site, Old Point Station

30312

Alkermes Investigational Site, Atlanta

30327

Alkermes Investigational Site, Atlanta

30342

Alkermes Investigational Site, Atlanta

31904

Alkermes Investigational Site, Columbus

32174

Alkermes Investigational Site, Ormond Beach

32751

Alkermes Investigational Site, Maitland

32960

Alkermes Investigational Site, Vero Beach

33462

Alkermes Investigational Site, Atlantis

33634

Alkermes Investigational Site, Tampa

34105

Alkermes Investigational Site, Naples

34209

Alkermes Investigational Site, Bradenton

34233

Alkermes Investigational Site, Sarasota

35058

Alkermes Investigational Site, Cullman

37064

Alkermes Investigational Site, Franklin

37922

Alkermes Investigational Site, Knoxville

43221

Alkermes Investigational Site, Columbus

44718

Alkermes Investigational Site, Canton

45417

Alkermes Investigational Site, Dayton

48202

Alkermes Investigational Site, Detroit

50314

Alkermes Investigational Site, Des Moines

55422

Alkermes Investigational Site, Golden Valley

60201

Alkermes Investigational Site, Evanston

63104

Alkermes Investigational Site, St Louis

63110

Alkermes Investigational Site, St Louis

63131

Alkermes Investigational Site, St Louis

66214

Alkermes Investigational Site, Lenexa

71301

Alkermes Investigational Site, Alexandria

73104

Alkermes Investigational Site, Oklahoma City

75231

Alkermes Investigational Site, Dallas

77030

Alkermes Investigational Site, Houston

77074

Alkermes Investigational Site, Houston

80112

Alkermes Investigational Site, Centennial

80209

Alkermes Investigational Site, Denver

81621

Alkermes Investigational Site, Basalt

85004

Alkermes Investigational Site, Phoenix

85704

Alkermes Investigational Site, Tucson

87106

Alkermes Investigational Site, Albuquerque

90806

Alkermes Investigational Site, Long Beach

92103

Alkermes Investigational Site, San Diego

98101

Alkermes Investigational Site, Seattle

98122

Alkermes Investigational Site, Seattle

98133

Alkermes Investigational Site, Seattle

06762

Alkermes Investigational Site, Middlebury

06905

Alkermes Investigational Site, Stamford

Unknown

Alkermes Investigational Site, Dresden

Alkermes Investigational Site, Leipzig

Alkermes Investigational Site, Ulm

Alkermes Investigational Site, Westerstede

80-803

Alkermes Investigational Site, Gdansk

40-123

Alkermes Investigational Site, Katowice

25-726

Alkermes Investigational Site, Kielce

90-324

Alkermes Investigational Site, Lodz

62-064

Alkermes Investigational Site, Plewiska

70-111

Alkermes Investigational Site, Szczecin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Alkermes, Inc.

INDUSTRY

lead

Biogen

INDUSTRY